{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:04:09Z","timestamp":1792019049307,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,21]]},"DOI":"10.7759\/cureus.49192","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:06:14Z","timestamp":1700597174000},"source":"Crossref","is-referenced-by-count":3,"title":["Exploring the High-Grade and Refractory Neurotoxicity of Teclistamab: An Underreported Entity"],"prefix":"10.7759","author":[{"given":"Forat","family":"Lutfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Nashatizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Hamideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17622","article-title":"Taking a BiTE out of the CAR T space race","volume":"195","author":"Patel A","year":"2021","unstructured":"Patel A, Oluwole O, Savani B, Dholaria B. Taking a BiTE out of the CAR T space race. Br J Haematol. 2021, 195:689-97. 10.1111\/bjh.17622","journal-title":"Br J Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW, et al.. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022, 387:495-505. 10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma. (2022). Accessed. June 1, 2023: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-m...."},{"key":"ref4","unstructured":"Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1). (2023). Accessed. June 1, 2023: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03145181."},{"key":"ref5","unstructured":"A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1). Accessed. June 1, 2023: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04557098."},{"key":"ref6","unstructured":"FDA. Tecvayli Highlights of Precribing Information. (2022). Accessed. June 1, 2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen AD","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, et al.. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022, 12:32. 10.1038\/s41408-022-00629-1","journal-title":"Blood Cancer J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2014.01.002","article-title":"Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL","volume":"59","author":"Os\u00f3rio C","year":"2014","unstructured":"Os\u00f3rio C, Chac\u00f3n PJ, White M, Kisiswa L, Wyatt S, Rodr\u00edguez-T\u00e9bar A, Davies AM. Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL. Mol Cell Neurosci. 2014, 59:24-36. 10.1016\/j.mcn.2014.01.002","journal-title":"Mol Cell Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy","volume":"70","author":"Marella M","year":"2022","unstructured":"Marella M, Yao X, Carreira V, et al.. Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy. J Histochem Cytochem. 2022, 70:273-87. 10.1369\/00221554221079579","journal-title":"J Histochem Cytochem"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen O","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, et al.. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021, 27:2099-103. 10.1038\/s41591-021-01564-7","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati P","year":"2020","unstructured":"Strati P, Nastoupil LJ, Westin J, et al.. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020, 4:3943-51. 10.1182\/bloodadvances.2020002228","journal-title":"Blood Adv"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies","volume":"11","author":"Zhou X","year":"2020","unstructured":"Zhou X, Rasche L, Kort\u00fcm KM, Danhof S, Hudecek M, Einsele H. Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies. Front Immunol. 2020, 11:620312. 10.3389\/fimmu.2020.620312","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/167814-exploring-the-high-grade-and-refractory-neurotoxicity-of-teclistamab-an-underreported-entity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:41Z","timestamp":1707508481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/167814-exploring-the-high-grade-and-refractory-neurotoxicity-of-teclistamab-an-underreported-entity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.49192","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,21]]}}}